Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 1Phase 1 1

Status

Completed 51Terminated 13Unknown 8Recruiting 7Withdrawn 4Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 133Genitourinary 43Breast 30Thoracic 29Head & Neck 29Lymphoid 23Gynecologic 16Sarcoma 12Tumor-Agnostic 7Other solid neoplasm 6Other hematologic neoplasm 3CNS 3Dermatologic 2Other neoplasm 1Myeloid 1

Conditions

Neoplasm Metastasis 5Neoplasms 3

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Gemcitabine × Tumor-Agnostic × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

National Cancer Institute, Naples

Phase 2 Recruiting
240 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06790602 2026-04-09

SWITCH

University of California, San Diego

Phase 2 Recruiting
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT06820255 2025-02-11

SELECTIO-UC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 4 Recruiting
135 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06696742 2024-11-20

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡